| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/0140-6736(91)90013-F |
| P953 | full work available at URL | https://api.elsevier.com/content/article/PII:014067369190013F?httpAccept=text/plain |
| https://api.elsevier.com/content/article/PII:014067369190013F?httpAccept=text/xml | ||
| P698 | PubMed publication ID | 1676091 |
| P2093 | author name string | A. P. Weetman | |
| P2860 | cites work | T and B cell reactivity to extraocular and skeletal muscle in Graves' ophthalmopathy | Q33647132 |
| Definition, at the molecular level, of a thyroglobulin-acetylcholinesterase shared epitope: study of its pathophysiological significance in patients with Graves' ophthalmopathy | Q35172325 | ||
| Epitopes on protein antigens: misconceptions and realities. | Q36576238 | ||
| Endocrine Ophthalmopathy: Current Ideas Concerning Etiology, Pathogenesis, and Treatment | Q40179925 | ||
| Patients with endocrine ophthalmopathy not associated with overt thyroid disease have multiple thyroid immunological abnormalities. | Q41222380 | ||
| Biological activity of autoantibodies associated with Graves' dermopathy | Q41312270 | ||
| Cross-reaction of eye muscle antibodies with thyroid tissue in thyroid-associated ophthalmopathy | Q41321244 | ||
| Thyrotropin potentiation of insulin-like growth factor-I dependent deoxribonucleic acid synthesis in FRTL-5 cells: mediation by an autocrine amplification factor(s). | Q41744580 | ||
| Use of corticosteroids to prevent progression of Graves' ophthalmopathy after radioiodine therapy for hyperthyroidism | Q43907362 | ||
| HLA immunogenetic heterogeneity in black American patients with Graves' disease. | Q53880886 | ||
| Association between Graves' ophthalmopathy and smoking | Q68088136 | ||
| Anti-muscle antibodies in Graves' ophthalmopathy | Q68541171 | ||
| Ability of monoclonal antibodies to the thyrotropin receptor to increase collagen synthesis in human fibroblasts: an assay which appears to measure exophthalmogenic immunoglobulins in Graves' sera | Q68950224 | ||
| Antibodies to porcine eye muscle in patients with Graves' ophthalmopathy: identification of serum immunoglobulins directed against unique determinants by immunoblotting and enzyme-linked immunosorbent assay | Q68985714 | ||
| Re-evaluation of eye muscle autoantibody determination in Graves' ophthalmopathy: failure to detect a specific antigen by use of enzyme-linked immunosorbent assay, indirect immunofluorescence, and immunoblotting techniques | Q69116314 | ||
| Cell-Mediated Immunity in the Exophthalmos of Graves' Disease as Demonstrated by the Migration Inhibition Factor (MIF) Test* | Q69587413 | ||
| Presence of antibodies in the sera of patients with Graves' disease recognizing a 23 kilodalton fibroblast protein | Q69680057 | ||
| Ophthalmopathic immunoglobulin in patients with Graves' ophthalmopathy | Q72586421 | ||
| P433 | issue | 8758 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pathophysiology | Q1135939 |
| eye disease | Q3041498 | ||
| P304 | page(s) | 25-28 | |
| P577 | publication date | 1991-07-01 | |
| 1991-07-06 | |||
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | Thyroid-associated eye disease: pathophysiology | |
| P478 | volume | 338 |
| Q30650830 | A 63 kDa skeletal muscle protein associated with eye muscle inflammation in Graves' disease is identified as the calcium binding protein calsequestrin |
| Q70674539 | A new ultrasonographic method to detect disease activity and predict response to immunosuppressive treatment in Graves ophthalmopathy |
| Q29299926 | Acute pre‐tibial myxoedema following radioiodine therapy for thyrotoxic Graves' disease |
| Q74821669 | An ultrastructural and systemic analysis of glycosaminoglycans in thyroid-associated ophthalmopathy |
| Q47901537 | Analysis of orbital T cells in thyroid-associated ophthalmopathy |
| Q71622356 | Antibody-dependent cell-mediated cytotoxicity against orbital target cells in thyroid-associated ophthalmopathy and related disorders; close relationship between serum cytotoxic antibodies and parameters of eye muscle dysfunction |
| Q73870904 | Antioxidant agents in the treatment of Graves' ophthalmopathy |
| Q35886822 | Assessing Graves' ophthalmopathy-specific quality of life in Korean patients |
| Q72561683 | Autoimmune thyroid disease |
| Q71736457 | Automated achromatic contrast and chromatic discrimination sensitivity testing in dysthyroid optic neuropathy |
| Q74261230 | Both Th1- and Th2-derived cytokines in serum are elevated in Graves' ophthalmopathy |
| Q74454288 | Correlation Between Clinical and Histological Analyses in Retroocular Connective Tissues and Extraocular Muscles from Patients with Graves' Ophthalmopathy |
| Q41497285 | Cytokines and thyroid function |
| Q72108611 | Demonstration of thyrotropin binding sites in orbital connective tissue: possible role in the pathogenesis of thyroid-associated ophthalmopathy |
| Q35305938 | Development of a disease specific quality of life questionnaire for patients with Graves' ophthalmopathy: the GO-QOL. |
| Q46835363 | Effect of smoking on retrobulbar blood flow in thyroid eye disease |
| Q52065352 | Elevated expression in situ of selectin and immunoglobulin superfamily type adhesion molecules in retroocular connective tissues from patients with Graves' ophthalmopathy. |
| Q36876492 | Endoscopic orbital decompression for dyscosmetic thyroid eye disease |
| Q41412461 | Eyeing up Graves' ophthalmopathy |
| Q45003766 | Failure to find an association of blood group P1 with thyroid-associated ophthalmopathy |
| Q51807164 | Genetic susceptibility to Graves' ophthalmopathy: the role of polymorphisms in proinflammatory cytokine genes. |
| Q35462752 | Glycosaminoglycans in thyroid-associated ophthalmopathy |
| Q78094456 | Graves' disease and thyroid associated ophthalmopathy triggered by 131I treatment of non-toxic goiter |
| Q34467124 | Histopathologic analysis of palpebral conjunctiva in thyroid-related orbitopathy (an american ophthalmological society thesis) |
| Q73048088 | Hyperthyroidism |
| Q71827904 | IgA autoantibodies against human eye muscle antigen detected by western blotting and immunohistochemical methods in Graves’ disease |
| Q71791459 | MR T2 Relaxation Time for the Assessment of Retrobulbar Inflammation in Graves' Ophthalmopathy |
| Q71791462 | New Assays for the Measurement of Serum Antibodies Reactive with Eye Muscle Membrane Antigens Confirm Their Significance in Thyroid-Associated Ophthalmopathy |
| Q73661214 | Objective evaluation of improvement in optic neuropathy following radiation therapy for thyroid eye disease |
| Q39159003 | Orbital Decompression for Thyroid Eye Disease |
| Q36585083 | Orbital endoscopic decompression in Graves ophthalmopathy |
| Q41955296 | Orbital fibroblast chemokine modulation: effects of dexamethasone and cyclosporin A. |
| Q72001621 | Plasma glycosaminoglycans in endocrine ophthalmopathy |
| Q43203691 | Prediction of LT4 replacement dose to achieve euthyroidism in subjects undergoing total thyroidectomy for benign thyroid disorders |
| Q47685471 | Proteomic analysis of the differences in orbital protein expression in thyroid orbitopathy. |
| Q34565430 | Quality of life in patients with Graves ophthalmopathy. |
| Q35221491 | Radiotherapy and ophthalmology: time for a friendly re-acquaintance |
| Q47573781 | Related quality of life questionnaire specific to dysthyroid ophthalmopathy evaluated in a population of patients with Graves' disease |
| Q73415094 | Results of a neurosurgical two-wall orbital decompression in the treatment of severe thyroid associated ophthalmopathy |
| Q41734159 | Retro-orbital autoimmunity |
| Q34154222 | Retrobulbar T cells from patients with Graves' ophthalmopathy are CD8+ and specifically recognize autologous fibroblasts. |
| Q35462736 | Role of connective tissue autoimmunity in Graves' ophthalmopathy |
| Q77723435 | Smoking and disease severity are independent determinants of serum adhesion molecule levels in Graves' ophthalmopathy |
| Q45907831 | Soluble IL-2 receptor levels in patients with Graves'ophthalmopathy |
| Q42505130 | Stimulation of extraocular muscle fibroblasts by cytokines and hypoxia: possible role in thyroid-associated ophthalmopathy |
| Q35314277 | T cells and fibroblasts in affected extraocular muscles in early and late thyroid associated ophthalmopathy |
| Q53539827 | Test-retest reliability of the GO-QOL: a disease-specific quality of life questionnaire for patients with Graves' ophthalmopathy. |
| Q40547836 | The enigma of Graves' ophthalmopathy. |
| Q53397181 | The role of IL-15 and selenium in Graves ophthalmopathy. |
| Q35462716 | The role of T lymphocytes in thyroid-associated ophthalmopathy |
| Q72271164 | The site of the autoantigen in dysthyroid eye disease: a significant negative |
| Q72870703 | Thyroid eye disease |
| Q35866148 | Thyroid-associated ophthalmopathy: a practical guide to classification, natural history and management |
| Q34147441 | Thyroid-associated ophthalmopathy: clinical features, pathogenesis, and management |
| Q40511567 | Thyroid-associated ophthalmopathy: pathogenesis and clinical management. |
| Q43674410 | Thyroid-associated orbitopathy developed during hormone replacement therapy |
| Q33955227 | Understanding the immunology of Graves' ophthalmopathy. Is it an autoimmune disease? |
| Q80895504 | [Thyroid-associated ophthalmopathy: physiopathology, endocrine status] |
Search more.